CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
A

Fasting plasma glucose

Glycemic & MetabolicLab test / biomarkerriskmodifiable
56
evidence score

Also known as: Fasting glucose, fasting glucose, fasting glucose concentrations, fpg, glucose

PREVENT status

Not a PREVENT input variable.

Causal support

trial evidence

Score components
lit volume: 20.5meta-analyses: 20trials: 15genetic: 0MR bonus:

References (111)

8 meta-analyses / systematic reviews

Clinical trials (138)

showing top 60
NCTTitleStatusTypeInterventions
NCT07284511Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel TrialRECRUITINGINTERVENTIONALTirzepatide, Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM), Carbohydrate Counting
NCT07070765Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity - SPRINTRECRUITINGINTERVENTIONALSodium-glucose transport-2 (SGLT-2) inhibitors, Standard medical treatment
NCT07214818Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Adult Patients With Nephrotic Syndrome: A Randomized Controlled TrialRECRUITINGINTERVENTIONALDapagliflozin, Empagliflozin, Standard Therapy
NCT07143773SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Double-blind, Placebo Controlled, National, Multicenter TrialRECRUITINGINTERVENTIONALSGLT-2 inhibitor, Placebo
NCT06609356Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 DiabetesRECRUITINGINTERVENTIONALStudy Visit 1, Placebo, Study Visit 2
NCT06655480Effect on Clinical Status, Structural and Functional Cardiac Parameters and Myocardial Fibrosis of Triple Combination Therapy With a Sodium-glucose Cotransporter 2 Inhibitor, Angiotensin Receptor/Neprilysin Inhibitor and Mineralocorticoid Receptor Antagonist in Patients With Advanced HFpEFRECRUITINGINTERVENTIONAL[ARNI + SGLTi + AMR], [SGLTi + previously taken RAAS blocker]
NCT07482020A Randomized Controlled Trial of SGLT2 Inhibitors to Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation and Comorbid Hypertension and Abnormal Glucose MetabolismRECRUITINGINTERVENTIONALSGLT-2 inhibitors, Placebo
NCT06562582STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical TriaRECRUITINGINTERVENTIONALBisoprolol Oral Tablet, Ramipril Oral Product, Dapagliflozin Oral Product
NCT06693934Jockey Club Precision Prevention Programme on Young Onset DiabetesRECRUITINGINTERVENTIONALRisk assessment with biogenetic and clinical test to predict diabetes risk, Oral glucose tolerance test (OGTT) and cardiovascular-kidney-metabolic (CKM) risk factors, Medication
NCT06528405The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney DiseaseRECRUITINGINTERVENTIONALdapagliflozin, Other anti-diabetic drug or no anti-diabetic drug, empagliflozin
NCT06579950The Effects of Cool Roofs on Health, Environmental, and Economic Outcomes: a Global Multi-center Cluster-randomized Controlled TrialRECRUITINGINTERVENTIONALCool roof
NCT06436326The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes: Testing the Moderating Effects of Socioeconomic and Cultural FactorsRECRUITINGINTERVENTIONALContinuous glucose monitor, Perinatal nursing care for gestational diabetes, Blood glucose meters (BGM)
NCT06751862The Effect of Simple Carbohydrates on the Development of Non-alcoholic Fatty Liver Disease (FROGLOSA)RECRUITINGINTERVENTIONAL150g of fat with glucose, 150g of fat with fructose, 150g of fat with sucrose
NCT05766735Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle ModificationRECRUITINGINTERVENTIONALRoutine Care + Glycemic Excursion Minimization (RC+GEM), Routine Care (RC)
NCT04662723Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.RECRUITINGINTERVENTIONALCorticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor
NCT05757791A Pilot, Phase II, Open-Label, Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive DisorderRECRUITINGINTERVENTIONALEmpagliflozin
NCT05431296Glucose Monitoring After Acute Myocardial Infarct in People With DiabetesRECRUITINGINTERVENTIONALDexcom ONE Continuous Glucose Monitoring System
NCT05305911Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).RECRUITINGINTERVENTIONALSGLT-2 inhibitors, Placebo
NCT07682350SGL-TX-PTDM: SGLT2i Effect on PTDM Development and Kidney Allograft Function in Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter TrialNOT YET RECRUITINGINTERVENTIONALSGLT2i, Placebo
NCT07056699Protocol V: San Antonio Site Sub Study: Can Pioglitazone Block SGLT2 Inhibitor-induced Stimulation of Lipolysis, Ketone Production and Liver Glucose Production in Type I Diabetic PatientsNOT YET RECRUITINGINTERVENTIONALDapagliflozin 10mg Tab, Pioglitazone 15 MG and 30mg, Placebo
NCT07592117A Cluster Randomised Controlled Trial (cRCT) Evaluating the Effects of Cool Roofs on Health, Environmental and Economic Outcomes in Tavua, FijiNOT YET RECRUITINGINTERVENTIONALCool roof
NCT06834893A Cluster Randomised Controlled Trial (cRCT) Evaluating the Effects of Cool Roofs on Health, Environmental and Economic Outcomes in Colima, MexicoNOT YET RECRUITINGINTERVENTIONALCool roof
NCT07482943The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan ProcedureNOT YET RECRUITINGINTERVENTIONALDapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
NCT07209527Evaluation of Truway Health-Sourced Portable Diagnostic Devices for Early Detection of Chronic Conditions in Outpatient Primary Care Settings: A Prospective Interventional StudyENROLLING BY INVITATIONINTERVENTIONALTruway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
NCT07065357Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor: a Randomised Controlled TrialENROLLING BY INVITATIONINTERVENTIONALEmpagliflozin (oral), Matching placebo
NCT07105917Sodium-dependent Glucose Transporters 2 Inhibitor for Neuroprotection in Patients With Acute Ischemic StrokeNOT YET RECRUITINGINTERVENTIONALSGLT-2 inhibitors, Standard medical treatment
NCT06933355Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension: A Randomized, Double-blind, Placebo Controlled Crossover TrialACTIVE NOT RECRUITINGINTERVENTIONALJARDIANCE 25mg, Placebo
NCT07367555Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients"COMPLETEDINTERVENTIONALOral 100 gram Empagliflozin tablet along with diet plan and exercise, Diet plan and exercise
NCT06570993A Cluster Randomised Controlled Trial (cRCT) Evaluating the Effects of Cool Roofs on Health, Environmental and Economic Outcomes in NiueCOMPLETEDINTERVENTIONALCool roof
NCT06448130Effect of Henagliflozin on the Remission of Prediabetes Population: A National Multicenter, Randomized Controlled StudyNOT YET RECRUITINGINTERVENTIONALHenagliflozin 5mg, Henagliflozin 10mg, Placebo
NCT06812429Effects of Sodium-Glucose Co-transporter 2 Inhibitors on InflammationCOMPLETEDINTERVENTIONALDapagliflozin (DAPA)
NCT04640493The Effect of Sodium Glucose Co-transporter 2 (SGLT2)-Inhibitors on Sleep Disordered Breathing in Heart Failure PatientsWITHDRAWNINTERVENTIONALDapagliflozin, WatchPat
NCT05874141Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, EgyptCOMPLETEDINTERVENTIONALHBA1C, Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides, Urine analysis and urinary albumin-to-creatinine ratio
NCT06117137The Impact Of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes MellitusCOMPLETEDINTERVENTIONALSGLT2 inhibitor
NCT05993897Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrium Remodeling in Non-valvular Paroxysmal Atrial Fibrillation PatientsUNKNOWNINTERVENTIONALSodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation
NCT05944432Real-Time Glucose Monitoring Using FreeStyle Libre 3 in Adults With Type 2 Diabetes On Basal Insulin Plus SGLT2 Inhibitor and/or GLP-1ACTIVE NOT RECRUITINGINTERVENTIONALFreeStyle Libre 3 Continuous Glucose Monitoring System., Self monitoring of blood glucose
NCT05975528Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 DiabetesUNKNOWNINTERVENTIONALSGLT2 inhibitor, Glimepiride
NCT05890131Implementation of Sodium-Glucose Cotransporter (SGLT)-2 Inhibitors in Patients With Heart Failure Through a New Digital StrategyCOMPLETEDINTERVENTIONALDigital letter
NCT05871502Glycemia and Ischemia Reperfusion Brain Injury in Patients With Acute Cerebral Infarction Treated With Mechanical ThrombectomyACTIVE NOT RECRUITINGINTERVENTIONALSubcutaneous blood glucose monitoring device
NCT06721442Effect of Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, on Ventricular Repolarization Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG StudyCOMPLETEDINTERVENTIONALDapagliflozin (DAPA)
NCT05676684SOdium-Glucose Cotransporter 2 Inhibitor With and Without an ALDosterone AntagonIst for Heart Failure With Preserved Ejection Fraction: a Two-centre Randomised Crossover TrialCOMPLETEDINTERVENTIONALDapagliflozin, Spironolactone + Dapagliflozin
NCT05735197Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Kidney Disease Progression and Bone Mineral Metabolism in Non-diabetic Patients With Chronic Kidney DiseaseCOMPLETEDINTERVENTIONALDapagliflozin 10mg Tab, Placebo
NCT07344922Impact of Sodium-Glucose Co-transporter 2 Inhibitors on Cardiovascular System and Anemia in Non-diabetic Chronic Kidney Disease Patients. A Randomized-Controlled Clinical TrialCOMPLETEDINTERVENTIONALDapagliflozin (10Mg Tab) along with standard medical therapy, Placebo
NCT06026787Clinical Value of Adding Dapagliflozin in Patients With Nephrotic SyndromeCOMPLETEDINTERVENTIONALDapagliflozin 10mg Tab
NCT05310916Evaluation of the Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Diabetic Retinopathy in Patients With Type 2 Diabetes MellitusUNKNOWNINTERVENTIONALDapagliflozin 10mg Tab plus another oral hypoglycemic agent, Two oral hypoglycemic agents other than dapagliflozin
NCT05601336Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in Infertile Women With Polycystic Ovary SyndromeUNKNOWNINTERVENTIONALDapagliflozin 5 MG, Metformin Hydrochloride 1000 MG, Dapagliflozin/Metformin
NCT05857085Impact of Additional Treatment With Empagliflozin or Semaglutide on Endothelial Function and Other Clinical Parameters and Biomarkers in T1DM PatientsCOMPLETEDINTERVENTIONALSemaglutide Pen Injector [Ozempic], Empagliflozin 10 MG
NCT05087823Measurements of Lipoproteins, Apolipoproteins, and Lipids in Three Separate Oral Challenges - Fat, Sugar, and Mixed Test MealsCOMPLETEDINTERVENTIONALLipid Challenge, Glucose Challenge, Mixed Meal Challenge
NCT05084079The Impact of Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in Short-term Intensive Insulin Therapy(SIIT)UNKNOWNINTERVENTIONALCSII with formula-based initial insulin regimen, CSII with weight-based initial insulin regimen
NCT05040087Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)ACTIVE NOT RECRUITINGINTERVENTIONALIntensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
NCT04818034The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary StudyCOMPLETEDINTERVENTIONALDapagliflozin
NCT04905589Effect of Combined Intake of Medium Chain Triglycerides (MCT) At Breakfast and Whey Protein Isolate (WPI) Preload At Lunch and Dinner on Diurnal Glucose and SatietyCOMPLETEDINTERVENTIONALBetaQuik™, WheyBasics, Iso-voluminous water
NCT05500937Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin-A Multicenter, Prospective, Random Controlled TrialUNKNOWNINTERVENTIONALUDCA
NCT04675255WU 360: Assessing the Impact of Integrase Strand Transfer Inhibitors (INSTI) to Protease Inhibitor (PI) Switch on Insulin Sensitivity and Fat Metabolism (ADIPOSITY): a Sub-study of DEFINECOMPLETEDINTERVENTIONALFrequently sampled glucose tolerance testing, abdominal subcutaneous adipose tissue biopsy, MRI scan to assess intrahepatic triglyceride content
NCT04778787Impact of Sodium-glucose Cotransporter Type 2 Inhibitors on the Course of Cardiorenal Syndrome in Acute Decompensation of Chronic Heart FailureCOMPLETEDINTERVENTIONALStandard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
NCT04450563The Effect of Low-dose Empagliflozin on Glucose Control in Adult Patients With Type 1 Diabetes on a Closed-loop Insulin System: a Randomized Cross-over Controlled TrialCOMPLETEDINTERVENTIONAL14-day outpatient intervention
NCT04078854The Impact of Sexual Health and Amputation Focused Education on Regulation of Glucose and Amputation Prevention (SAFER GAP)TERMINATEDINTERVENTIONALDiabetes education
NCT05764811Mechanism of the Effect by Sodium-glucose Cotransporter-2 Inhibitor on Obesity Associated CardiomyopathyCOMPLETEDINTERVENTIONALCanagliflozin 100mg
NCT05283057Effect of Sodium Glucose Transporter 2 Inhibitor Empagliflozin on Proteinuria and Kidney Disease Progression in Patients With Non-diabetic Glomerulonephritis- A Randomized Controlled TrialCOMPLETEDINTERVENTIONALEmpagliflozin 25 MG, placebo
NCT04042142In-depth Studies of Glucagon Resistance on Hepatic Glucose, Fatty Acid and Triglyceride Kinetics and Generation of Toxic Lipid Intermediates in NAFLD and NASH.COMPLETEDINTERVENTIONALglucagon

Genetic associations (0)

None linked.